Article Figures & Data
Figures
- Figure 1.
Age-adjusted DCIS incidence trends, overall and by age and race. APC in the DCIS incidence rate in the United States, 2000–2014, overall (A), age group (B), and by race (C). Asterisk (*) indicates that the APC is statistically significantly different from zero (P < 0.05). To highlight trends, the scales of the y-axes vary.
- Figure 2.
Trends in tumor characteristics among women diagnosed with DCIS. Proportions of women diagnosed with ER-positive and PR-positive DCIS (A), grade I, II, and III DCIS (B), and small (1–10 mm), intermediate (11–30 mm), and large (>30 mm) DCIS (C) in the United States, 2000–2014. Only cases with known tumor features are included in the analyses.
- Figure 3.
Trends in tumor characteristics among women diagnosed with DCIS; subgroup analyses. Proportions of women diagnosed with ER-positive and progesterone (PR)-positive DCIS, grade I, II, and III DCIS, and small (1–10 mm), intermediate (11–30 mm), large (>30 mm) DCIS among white women (A) and black women (B), in the United States, 2000–2014. Only cases with known tumor features are included in the analyses.
- Figure 4.
Mammogram utilization (1987–2015) and DCIS incidence (1992–2014), by age groups and race. Crude mammogram utilization (NIHS data) and DCIS incidence (SEER 13) rates among women of all races ages 40–49 years (A), 50–64 years (B), and greater than 65 years (C), and for all ages by race (D). Scales for DCIS incidence and mammogram utilization on the left and right sides of the graphs, respectively.
- Figure 5.
Incidence and mortality rates of female breast, cervical, and colorectal (male and female) cancers in the United States, 1999–2015. Relative rates are obtained by rescaling the actual rates with respect to the baseline rates in 1999. Data extracted from the U.S. Cancer Statistics Data Visualizations Tool (12).
Tables
- Table 1.
Trends in patient and tumor features
Total (N = 145,670) 2000–03 (N = 34,554) 2004–07 (N = 37,188) 2008–11 (N = 41,783) 2012–2014 (N = 32,145) n (%) n (%) n (%) n (%) n (%) Pa Age <0.001 20–44 years 17,860 (12.3) 4,503 (13) 4,725 (12.7) 4,999 (12) 3,633 (11.3) 45–54 years 40,512 (27.8) 9,534 (27.6) 10,710 (28.8) 11,767 (28.2) 8,501 (26.4) 55–69 years 56,512 (38.8) 12,510 (36.2) 13,782 (37.1) 16,554 (39.6) 13,666 (42.5) ≥70 years 30,786 (21.1) 8,007 (23.2) 7,971 (21.4) 8,463 (20.3) 6,345 (19.7) Race <0.001 White 113,396 (77.8) 28,125 (81.4) 29,440 (79.2) 32,084 (76.8) 23,747 (73.9) Black 15,712 (10.8) 3,222 (9.3) 3,897 (10.5) 4,647 (11.1) 3,946 (12.3) Other 15,112 (10.4) 2,978 (8.6) 3,561 (9.5) 4,609 (11.0) 3,964 (12.0) Unknown 1,450 (1.0) 229 (0.7) 290 (0.8) 443 (1.1) 488 (1.5) ER status <0.001 Positive 83,168 (57.1) 4,857 (14.1) 21,276 (57.2) 30,865 (73.9) 26,170 (81.4) Negative 14,592 (10.0) 1,198 (3.5) 4,521 (12.2) 5,125 (12.3) 3,748 (11.7) Unknown 47,910 (32.9) 28,499 (82.5) 11,391 (30.6) 5,793 (13.9) 2,227 (6.9) PR status <0.001 Positive 68,961 (47.3) 3,909 (11.3) 17,314 (46.6) 25,676 (61.5) 22,062 (68.6) Negative 22,783 (15.6) 1,731 (5) 6,732 (18.1) 8,212 (19.7) 6,108 (19) Unknown 53,926 (37.0) 28,914 (83.7) 13,142 (35.3) 7,895 (18.9) 3,975 (12.4) Tumor grade <0.001 Grade I 17,359 (11.9) 3,854 (11.2) 4,282 (11.5) 5,081 (12.2) 4,142 (12.9) Grade II 50,862 (34.9) 10,301 (29.8) 12,553 (33.8) 15,450 (37) 12,558 (39.1) Grade III/IV 55,060 (37.8) 11,848 (34.3) 14,803 (39.8) 16,177 (38.7) 12,232 (38.1) Unknown 22,389 (15.4) 8,551 (24.7) 5,550 (14.9) 5,075 (12.1) 3,213 (10) Tumor size <0.001 1–10 mm 49,926 (34.3) 9,865 (28.6) 12,612 (33.9) 15,305 (36.6) 12,144 (37.8) 11–30 mm 37,351 (25.6) 7,510 (21.8) 9,027 (24.3) 11,038 (26.4) 9,776 (30.4) >30 mm 13,162 (9.0) 2,204 (6.4) 3,055 (8.2) 4,156 (9.9) 3,747 (11.7) Unknown 45,231 (31.1) 14,891 (43.2) 12,494 (33.6) 11,284 (27) 6,478 (20.2) ↵aχ2 test.
- Table 2.
Tumor features in patients diagnosed between 2012–2014
n (%) Known tumor grade (n = 28,932) Grade I 4,142 (14.3) Grade II 12,558 (43.4) Grade III/IV 12,232 (42.3) Known ER Status (n = 29,918) ER-positive 26,170 (87.5) ER-negative 3,748 (12.5) Known PR Status (n = 28,170) PR-positive 22,062 (78.3) PR-negative 6,108 (21.7) Known tumor size (n = 25,667) 1–10 mm 12,144 (47.3) 11–30 mm 9,776 (38.1) >30 mm 3,747 (14.6) Known tumor grade, ER and/or PR Statusa (n = 26,552) Low riskb 14,762 (55.6) Non-low risk 11,790 (44.4)
Supplementary Data
- Supplementary Figure 1 - Figure S1: Age-adjusted ductal carcinoma in situ (DCIS) incidence trends.
- Supplementary Materials - Contains ICD-0-3 histology codes included in the study
- Supplementary Table 1 - Table S1: Tumor features in patients diagnosed between 2000 and 2014.
Volume 28, Issue 8
